Pamela Ann Connealy - 06 Dec 2021 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Financial Officer
Signature
/s/ Pamela Connealy
Issuer symbol
PYXS
Transactions as of
06 Dec 2021
Net transactions value
$0
Form type
4
Filing time
07 Dec 2021, 14:36:50 UTC
Previous filing
07 Oct 2021
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to buy) Award $0 +52,944 $0.000000 52,944 06 Dec 2021 Common Stock 52,944 $9.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options vest 25% on July 19, 2022, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.